Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
Murata Y, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Takeshita M, Ito K, Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N. Murata Y, et al. Among authors: kawamura t. JTO Clin Res Rep. 2023 Oct 20;4(12):100593. doi: 10.1016/j.jtocrr.2023.100593. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38046378 Free PMC article.
Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients.
Takeshita J, Masago K, Fujita S, Hata A, Kaji R, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Tomii K, Shintani T, Takayama K, Kokubo M, Katakami N. Takeshita J, et al. Among authors: kawamura t. Mol Clin Oncol. 2014 May;2(3):454-460. doi: 10.3892/mco.2014.249. Epub 2014 Jan 28. Mol Clin Oncol. 2014. PMID: 24772317 Free PMC article.
Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC.
Miyawaki T, Naito T, Kodama A, Nishioka N, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Notsu A, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: kawamura t. JTO Clin Res Rep. 2020 Mar 4;1(2):100020. doi: 10.1016/j.jtocrr.2020.100020. eCollection 2020 Jun. JTO Clin Res Rep. 2020. PMID: 34589927 Free PMC article.
Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report.
Kunimasa K, Inoue T, Matsueda K, Kawamura T, Tamiya M, Nishino K, Kumagai T. Kunimasa K, et al. Among authors: kawamura t. JTO Clin Res Rep. 2021 Dec 31;3(2):100272. doi: 10.1016/j.jtocrr.2021.100272. eCollection 2022 Feb. JTO Clin Res Rep. 2021. PMID: 35072122 Free PMC article.
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N. Tanaka K, et al. Among authors: kawamura t. J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929. J Thorac Oncol. 2013. PMID: 23591159 Free article.
Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Miyawaki T, Kenmotsu H, Mori K, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: kawamura t. Clin Lung Cancer. 2020 Sep;21(5):e405-e414. doi: 10.1016/j.cllc.2020.02.012. Epub 2020 Feb 26. Clin Lung Cancer. 2020. PMID: 32205040 Clinical Trial.
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Nakashima K, Ozawa Y, Daga H, Imai H, Tamiya M, Tokito T, Kawamura T, Akamatsu H, Tsuboguchi Y, Takahashi T, Yamamoto N, Mori K, Murakami H. Nakashima K, et al. Among authors: kawamura t. Invest New Drugs. 2020 Dec;38(6):1854-1861. doi: 10.1007/s10637-020-00943-0. Epub 2020 May 18. Invest New Drugs. 2020. PMID: 32424780 Clinical Trial.
3,089 results